About us

Lys Therapeutics, first-in-class biotherapies against neurological diseases

Meet our team

Dr. Thibault HONEGGER, PhD

Co-founder, member of the Strategic Committee

Suivre un lien ajouté manuellement

Philippe DUJARDIN

Co-founder, acting CFO, member of the Strategic Committee

Suivre un lien ajouté manuellement

Dr. Manuel BLANC, PhD, MBA

Co-founder, CEO, President of the Strategic Committee

Suivre un lien ajouté manuellement

Dr. François FOSSIEZ, PhD

Head of CMC

Suivre un lien ajouté manuellement

Dr. Flavie LESEPT, PhD

Project Manager, Preclinical R&D

Suivre un lien ajouté manuellement

Pr. Denis VIVIEN, PhD, PU-PH

President of the Scientific Advisory Board – acting CSO

Suivre un lien ajouté manuellement

Werner KLINGER

Head of IT and data protection

Suivre un lien ajouté manuellement
Dr. Manuel BLANC

Dr. Manuel BLANC

PhD, MBA

Co-founder, CEO, President of the Strategic Committee

Dr. Thibault HONEGGER

Dr. Thibault HONEGGER

PhD

Co-founder, member of the Strategic Committee

Philippe DUJARDIN

Philippe DUJARDIN

Co-founder, member of the Strategic Committee

Pr. Denis VIVIEN

Pr. Denis VIVIEN

PhD, PU-PH

President of the Scientific Advisory Board – acting CSO

Dr. François FOSSIEZ

Dr. François FOSSIEZ

PhD

Head of CMC

Dr. Flavie LESEPT

Dr. Flavie LESEPT

PhD

Project Manager, Preclinical R&D

Werner KLINGER

Werner KLINGER

Head of IT and data protection

Scientific Advisory Board

President of the SAB: Pr. Denis Vivien (PhD, PU-PH), France, co-inventor of Glunomab & expert of tPA, head of the Research Institute “Blood and Brain @ Caen-Normandie”

Dr. Richard Macrez (MD, PhD), France, co-inventor of Glunomab, assistant professor and emergency physician, head of Emergency Unit at Caen-Normandie Hospital

Dr. Désiré COLLEN (MD, PhD), Belgium, inventor of rtPA (alteplase) still the most effective drug for thrombolytic therapy of acute myocardial infarction and ischemic stroke

Pr. Diederik DIPPEL (MD, PhD), the Netherlands, neurologist, co-director of the Erasmus University MC Stroke Center

Pr. Yannick BÉJOT (MD, PhD), France, neurologist, head of Neurology at Dijon-Bourgogne hospital

Pr. Joan MONTANER (MD, PhD), Spain, neurologist, head of Neurovascular Research at the Vall d’Hebron Research Institute

Via BB@C Institute: Pr. Martin Dichgans (MD, PhD), Germany, neurologist, Director of the Institute of Stroke and Dementia Research (Medical Center of the University of Munich), head of the World Stroke Organization

Via BB@C Institute:  Pr. Eng Lo (MD, PhD), USA, neurologist, Professor of Neurology and Radiology, Harvard Medical School, and Research Staff, Massachusetts General Hospital

Science

An outstanding scientific background

Gluno(zu)mab® : a monoclonal antibody counteracting the strong toxicity
triggered by the interaction between tissue plasminogen activator (tPA) and NMDA receptors

Mechanism of Action (MoA) of Gluno(zu)mab®:

In the pathophysiology of neurological diseases such as stroke or multiple sclerosis, one protease called tissue plasminogen activator (tPA) is triggering off-target toxicity via hyperactivation of NMDA receptors (NMDAr) causing deleterious increase of the permeability of the blood brain barrier and strong neuronal excitotoxicity.

Gluno(zu)mab® counteracts this tPA-dependent strong toxicity without perturbing basal NMDAr functioning.

Scientific publications of Lys Therapeutics and Pr. Denis Vivien et al.:

Pipeline

Clinical development of Gluno(zu)mab®

News

Lys Therapeutics is laureate and Grand-Prix i-Lab 2021

Les 243 lauréats de l'édition 2021 du Concours d'innovation - qui se décline en 3 volets complémentaires : i-Lab, i-PhD et i-Nov  - ont été dévoilés, jeudi 8 juillet 2021. La cérémonie a notamment mis à l'honneur, les 69 lauréats…

Career

We don’t have open positions at the moment, stay tuned!

Contact us

Headquarters: Caen, France

Campus Jules HOROWITZ
Cyceron, Boulevard Henri Becquerel,
14000 CAEN, France

Main offices: Lyon, France

47 Boulevard du 11 Novembre 1918,
69100 VILLEURBANNE, France